CureVac acquisition advances as cash runway secured to 2028
CureVac's third-quarter performance beat expectations thanks to one-off items and litigation settlements, while management reiterated that existing Cash reserves can fund operations through 2028. Regulatory approvals in Germany and BioNTech's ongoing public offer keep the planned acquisition on schedule.
Published on 11/25/2025 at 09:23 am EST - Modified on 11/25/2025 at 08:48 am EST



















